Obesity is also associated with both increased PsA incidence and reduced therapeutic response to biologic agents (23, 24)
Understanding your personal risk factors for weight regainincluding genetic predispositions in GLP-1 signaling pathways and metabolic markerscan help inform a more targeted conversation with your provider about realistic treatment timelines and discontinuation strategies
In late 2023, the FDA aggressively updated its bulk drug substances list
Pierno S, Camerino GM, Cannone M, Liantonio A, De Bellis M, Digennaro C, Gramegna G, De Luca A, Germinario E, Danieli-Betto D, Betto R, Dobrowolny G, Rizzuto E, Musaro A, Desaphy JF, Camerino DC (2014) Paracrine effects of IGF-1 overexpression on the functional decline due to skeletal muscle disuse: molecular and functional evaluation in hindlimb unloaded MLC/mIgf-1 transgenic mice
The conformational and biological analysis of a cyclic anti-obesity peptide from the C-terminal domain of human growth hormone